Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Dana R. Van De Hey"'
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Autor:
Dustin A. Deming, Melissa C. Skala, Michael A. Newton, Kristina A. Matkowskyj, Paraic A. Kenny, Benjamin M. Parsons, Kayla K. Lemmon, Mark E. Burkard, Linda Clipson, Rebecca A. DeStefanis, Gioia Chengcheng Sha, Demetra P. Korkos, Mitchell G. Depke, Dana R. Van De Hey, Alexander E. Yueh, Tyler M. Foley, Cheri A. Pasch, Jeremy D. Kratz, Peter F. Favreau, Susan N. Payne, Stephanie L. Fricke
Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3797d51c82d44138bbd5766b7be6a207
https://doi.org/10.1158/1535-7163.22507717.v1
https://doi.org/10.1158/1535-7163.22507717.v1
Autor:
Dustin A. Deming, Michael A. Newton, Kristina A. Matkowskyj, Molly E Maher, Linda Clipson, Demetra P Korkos, Dana R Van De Hey, Alex E. Yueh, Cheri A. Pasch, Susan N. Payne, Tyler M Foley
S1. AP spheroids were plated and allowed to mature for 48 hours. S2. To address the issue of potentially slower growth of the spheres with the largest initial sizes, a change-point analysis was performed. S3. AP mice were treated with control (A) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b40b59770a6d2023987e8d876e86d4
https://doi.org/10.1158/1541-7786.22515181
https://doi.org/10.1158/1541-7786.22515181
Autor:
Dustin A. Deming, Melissa C. Skala, Michael A. Newton, Kristina A. Matkowskyj, Paraic A. Kenny, Benjamin M. Parsons, Kayla K. Lemmon, Mark E. Burkard, Linda Clipson, Rebecca A. DeStefanis, Gioia Chengcheng Sha, Demetra P. Korkos, Mitchell G. Depke, Dana R. Van De Hey, Alexander E. Yueh, Tyler M. Foley, Cheri A. Pasch, Jeremy D. Kratz, Peter F. Favreau, Susan N. Payne, Stephanie L. Fricke
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61eef4938e53e1487200610ced459f4f
https://doi.org/10.1158/1535-7163.c.6538765.v1
https://doi.org/10.1158/1535-7163.c.6538765.v1
Autor:
Alexander E Yueh, Susan N Payne, Alyssa A Leystra, Dana R Van De Hey, Tyler M Foley, Cheri A Pasch, Linda Clipson, Kristina A Matkowskyj, Dustin A Deming
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0148730 (2016)
The phosphoinositide 3-kinase (PI3K) signaling pathway is critical for multiple important cellular functions, and is one of the most commonly altered pathways in human cancers. We previously developed a mouse model in which colon cancers were initiat
Externí odkaz:
https://doaj.org/article/43d47cd50a744f7b938ac68fd1de464b
Autor:
Adam Pagenkopf, Michael G. Johnson, Dana R. Van De Hey, Athanasios Papadas, Susan N. Payne, Dustin A. Deming, Linda Clipson, Philip B. Emmerich, Kristina A. Matkowskyj, Peiman Hematti, Natalie S. Callander, Shigeki Miyamoto, Fotis Asimakopoulos, Chelsea Hope
Publikováno v:
The Journal of Immunology. 199:1933-1941
Colorectal cancer originates within immunologically complex microenvironments. To date, the benefits of immunotherapy have been modest, except in neoantigen-laden mismatch repair–deficient tumors. Approaches to enhance tumor-infiltrating lymphocyte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f021afd59b0e9ddccbc3bb4e97bdbd
https://doi.org/10.4049/jimmunol.1700529
https://doi.org/10.4049/jimmunol.1700529
Autor:
Molly Maher, Cheri A. Pasch, Demetra P. Korkos, Dana R. Van De Hey, Alex E. Yueh, Linda Clipson, Dustin A. Deming, Susan N. Payne, Kristina A. Matkowskyj, Tyler M. Foley, Michael A. Newton
Publikováno v:
Molecular Cancer Research. 15:317-327
Therapeutic targeting of the PI3K pathway is an active area of research in multiple cancer types, including breast and endometrial cancers. This pathway is commonly altered in cancer and plays an integral role in numerous vital cellular functions. Mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ae224d931c462855939e84166157dcd
https://doi.org/10.1158/1541-7786.mcr-16-0256
https://doi.org/10.1158/1541-7786.mcr-16-0256
Autor:
Demetra P. Korkos, Stephanie L. Fricke, Rebecca A. DeStefanis, Dustin A. Deming, Gioia Sha, Alyssa K. DeZeeuw, Carley M. Sprackling, Jeremy D. Kratz, Alexander E. Yueh, Michael A. Newton, Dana R. Van De Hey, Aurora Greane, Christopher L. Babiarz, Susan N. Payne, Devon Miller, Kristina A. Matkowskyj, Linda Clipson, Cheri A. Pasch
Publikováno v:
Molecular Cancer Research. 18:B27-B27
Colorectal cancer (CRC) is a leading cause of cancer-related death. PIK3CA mutations are common, leading to a constitutively active phosphoinositide-3 kinase (PI3K). An effective means to target this pathway has yet to be identified. We investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a46aff379080e1d9c4d724cf1434d480
https://doi.org/10.1158/1557-3125.pi3k-mtor18-b27
https://doi.org/10.1158/1557-3125.pi3k-mtor18-b27
Autor:
Tyler M, Foley, Susan N, Payne, Cheri A, Pasch, Alex E, Yueh, Dana R, Van De Hey, Demetra P, Korkos, Linda, Clipson, Molly E, Maher, Kristina A, Matkowskyj, Michael A, Newton, Dustin A, Deming
Publikováno v:
Molecular cancer research : MCR. 15(3)
Therapeutic targeting of the PI3K pathway is an active area of research in multiple cancer types, including breast and endometrial cancers. This pathway is commonly altered in cancer and plays an integral role in numerous vital cellular functions. Mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::843898c220259880866535f1221dcae8
https://pubmed.ncbi.nlm.nih.gov/28184015
https://pubmed.ncbi.nlm.nih.gov/28184015
Autor:
Tyler M. Foley, Dustin A. Deming, Susan N. Payne, Cheri A. Pasch, Kristina A. Matkowskyj, Alexander E. Yueh, Alyssa A. Leystra, Dana R. Van De Hey, Linda Clipson
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 2, p e0148730 (2016)
PLoS ONE, Vol 11, Iss 2, p e0148730 (2016)
The phosphoinositide 3-kinase (PI3K) signaling pathway is critical for multiple important cellular functions, and is one of the most commonly altered pathways in human cancers. We previously developed a mouse model in which colon cancers were initiat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9951f3153f68579ae72cf6af07132a7
https://pubmed.ncbi.nlm.nih.gov/26863299
https://pubmed.ncbi.nlm.nih.gov/26863299
Autor:
Linda Clipson, Dustin A. Deming, Dana R. Van De Hey, Cheri A. Pasch, Susan N. Payne, Kristina A. Matkowskyj
Publikováno v:
Cancer Research. 77:4929-4929
Background: The microbiome of the colon has been shown to play a role in colon cancer tumorigenesis. Inflammation is a key step in the formation of tumors, and it is possible that microbiota induce this inflammation, further stimulating tumor growth.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f5444e9dfb930a36d010cc735b748a5
https://doi.org/10.1158/1538-7445.am2017-4929
https://doi.org/10.1158/1538-7445.am2017-4929